Source:http://linkedlifedata.com/resource/pubmed/id/18972276
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2008-10-30
|
| pubmed:databankReference | |
| pubmed:abstractText |
Systemic corticosteroids and additional short-acting beta2-agonists are commonly used in exacerbations of chronic obstructive pulmonary disease (COPD). In this double-blind study, the combination of a high-dose inhaled corticosteroid with a rapid-onset long-acting beta2-agonist was evaluated in the treatment of out-patient COPD exacerbations. The primary aim was to compare 14-day treatment effects of budesonide/formoterol to placebo on sputum eosinophils and, secondarily, on other indices of inflammation, forced expiratory flow in one second (FEV(1)), symptoms, health status, and adverse events. Forty-five patients not using steroids (37 male, 21/24 current/ex smoker, median packyears 38, age 65 years, FEV(1) 61% predicted), experiencing a COPD exacerbation, were treated at home with budesonide/formoterol (320/9 microg 4 times daily), prednisolone (30 mg daily), or placebo for 14 days. Sputum eosinophils were significantly reduced by budesonide/formoterol (-57%) compared to placebo (+24%) (p = 0.01). Budesonide/formoterol reduced total symptom scores significantly (p = 0.01) compared to placebo. The increase in FEV(1) by 2 weeks of treatment with budesonide/formoterol (125 ml) was not significantly different from that of placebo (43 ml) (p = 0.07). Budesonide/ formoterol treatment did not suppress morning serum cortisol compared to placebo (-16%; p = 0.50). In conclusion, budesonide/formoterol reduces sputum eosinophils and improves symptoms in the treatment of out-patient COPD exacerbations.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Bronchodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Budesonide,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Ethanolamines,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/formoterol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1541-2563
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
5
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
282-90
|
| pubmed:dateRevised |
2009-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:18972276-Administration, Inhalation,
pubmed-meshheading:18972276-Administration, Oral,
pubmed-meshheading:18972276-Aged,
pubmed-meshheading:18972276-Anti-Inflammatory Agents,
pubmed-meshheading:18972276-Bronchodilator Agents,
pubmed-meshheading:18972276-Budesonide,
pubmed-meshheading:18972276-Double-Blind Method,
pubmed-meshheading:18972276-Drug Combinations,
pubmed-meshheading:18972276-Eosinophils,
pubmed-meshheading:18972276-Ethanolamines,
pubmed-meshheading:18972276-Female,
pubmed-meshheading:18972276-Humans,
pubmed-meshheading:18972276-Male,
pubmed-meshheading:18972276-Middle Aged,
pubmed-meshheading:18972276-Prednisolone,
pubmed-meshheading:18972276-Pulmonary Disease, Chronic Obstructive,
pubmed-meshheading:18972276-Respiratory Function Tests,
pubmed-meshheading:18972276-Sputum,
pubmed-meshheading:18972276-Treatment Outcome
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
|
| pubmed:affiliation |
Groningen Research Institute for Asthma and COPD, Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ebathoorn@gmail.com
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|